Dmitry I. Trukhan , Natalya V. Bagisheva
Abstract
The use of diuretics in arterial hypertension is pathogenetically justified, which is due to the significant role of an increase in the volume of circulating blood and the retention of sodium ions in the internal environment of the body, in increasing blood pressure. In clinical guidelines, the choice of a diuretic for the treatment of hypertension is limited to 3 drugs: hydrochlorothiazide, chlorthalidone and indapamide. Thiazide and thiazide-like diuretics are often combined into a single group of "thiazides", however, they have significant differences in the mechanism of their action, clinical effects, drug safety profile, partly in the parameters of the effectiveness of blood pressure control, as well as the evidence base in randomized clinical trials. In the first part of the review, along with evidence of the effectiveness of the use of diuretics in arterial hypertension, various aspects of the drug safety of drugs in this group are considered, both possible metabolic disorders and more rare, but possible disorders of the organ of vision, skin adverse reactions and the risk of acute respiratory distress. -syndrome. The second part of the review considers the efficacy and safety of the thiazide-like diuretic indapamide.
Key words: arterial hypertension, rational pharmacotherapy, drug safety, diuretics, treatment, indapamide, hydrochlorothiazide, chlorthalidone.
About the Author
Dmitry I. Trukhan 1 , Natalya V. Bagisheva 11 Omsk State Medical University, Omsk, Russia
References
1. Трухан Д.И., Филимонов С.Н. Болезни сердечно-сосудистой системы: клиника, диагностика и лечение. СПб.: СпецЛит, 2016. URL: https: //elibrary.ru/item.asp?id=36478361 [Truhan D.I., Filimonov S.N. Bolezni serdechno-sosudistoj sistemy: klinika, diagnostika i lechenie. Saint Petersburg: SpecLit, 2016. URL: https: //elibrary.ru/item.asp?id=36478361 (in Russian).]
2. Викторова И.А., Лисняк М.В., Трухан Д.И. Влияние социальнодемографических и психологических факторов на приверженность к антигипертензивной терапии. Сибирское медицинское обозрение. 2014; 5 (89): 75–8. URL: https: //www.elibrary.ru/item. asp?id=22561261 [Viktorova I.A., Lisnyak M.V., Truhan D.I. Vliyanie social'no-demograficheskih i psihologicheskih faktorov na priverzhennost' k antigipertenzivnoj terapii. Sibirskoe medicinskoe obozrenie. 2014; 5 (89): 75–8. URL: https: //www.elibrary.ru/item.asp?id=22561261 (in Russian).]
3. Демографический ежегодник России. 2021. URL: https: //gks.ru/bgd/regl/B21_16/Main.htm [Demograficheskij ezhegodnik Rossii. 2021. URL: https: //gks.ru/bgd/regl/B21_16/Main.htm (in Russian).]
4. Трухан Д.И., Филимонов С.Н., Темникова Е.А. Болезни сердечнососудистой системы: клиника, диагностика и лечение. Гериатрические аспекты в кардиологии. СПб.: СпецЛит, 2022. URL: https: //elibrary.ru/item.asp?id=48110916 [Trukhan D.I., Filimonov S.N., Temnikova E.A. Bolezni serdechno-sosudistoi sistemy: klinika, diagnostika i lechenie. Geriatricheskie aspekty v kardiologii. St. Petersburg: SpetsLit, 2022. Rezhim dostupa: https: //elibrary.ru/item.asp?id=48110916 (in Russian).]
5. Национальные рекомендации по рациональной фармакотерапии больных сердечно-сосудистыми заболеваниями. Кардиоваскулярная терапия и профилактика 2009; 8 (6), Приложение 4. URL: https: //scardio.ru/en/guidelines/rsc_guidelines/nacionalnye_rekomendacii_po_racionalnoy_farmakoterapii_bolnyh_serde chnososudistymi_zabolevaniyami/ [Nacional'nye rekomendacii po racional'noj farmakoterapii bol'nyh serdechno-sosudistymi zabolevaniyami. Kardiovaskulyarnaya terapiya i profilaktika 2009; 8 (6), Prilozhenie 4. URL: https: //scardio.ru/en/guidelines/rsc_guidelines/nacionalnye_rekomendacii_po _racionalnoy_farmakoterapii_bolnyh_serdechnososudistymi_zabo levaniyami/ (in Russian).]
6. Трухан Д.И., Тарасова Л.В. Рациональная фармакотерапия и лекарственная безопасность в кардиологии. Справочник поликлинического врача. 2013; 5: 21–6. URL: https: //elibrary.ru/item.asp? id=21746647 [Truhan D.I., Tarasova L.V. Racional'naya farmakoterapiya i lekarstvennaya bezopasnost' v kardiologii. Spravochnik poliklinicheskogo vracha. 2013; 5: 21–6. URL: https: //elibrary.ru/item.asp? id=21746647 (in Russian).]
7. Трухан Д.И. Выбор лекарственного препарата с позиций рациональной фармакотерапии. Consilium Medicum. 2013; 11: 45–9. URL: https: //elibrary.ru/item.asp?id=21014169 [Truhan D.I. Vybor lekarstvennogo preparata s pozicij racional'noj farmakoterapii. Consilium Medicum. 2013; 11: 45–9. URL: https: //elibrary.ru/item.asp?id=21014169 (in Russian).]
8. Трухан Д.И., Коншу Н.В. Рациональная фармакотерапия в клинике внутренних болезней сквозь призму мультиморбидности и лекарственной безопасности. Справочник поликлинического врача. 2019; 02: 10–8. URL: https: //www.elibrary.ru/item.asp? id=44162870 [Truhan D.I., Konshu N.V. Racional'naya farmakoterapiya v klinike vnutrennih boleznej skvoz' prizmu mul'timorbidnosti i lekarstvennoj bezopasnosti. Spravochnik poliklinicheskogo vracha. 2019; 02: 10–8. URL: https: //www.elibrary.ru/item.asp?id=44162870 (in Russian).]
9. Трухан Д.И. Рациональная фармакотерапия в реальной клинической практике сквозь призму мультиморбидности и лекарственной безопасности. Клинический разбор в общей медицине. 2020; 2: 29-39. DOI: 10.47407/kr2020.1.2.00015 [Truhan D.I. Racional'naya farmakoterapiya v real'noj klinicheskoj praktike skvoz' prizmu mul'timorbidnosti i lekarstvennoj bezopasnosti. Clinical review for general practice. 2020; 2: 29-39. DOI: 10.47407/kr2020.1.2.00015 (in Russian).]
10. Tamargo J, Segura J, Ruilope LM. Diuretics in the treatment of hypertension. Part 1: thiazide and thiazide-like diuretics. Expert Opin Pharmacother 2014; 15 (4): 527–47. DOI: 10.1517/14656566. 2014.879118
11. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39 (33): 3021–104. DOI: 10.1093/eurheartj/ehy339.
12. Клинические рекомендации Артериальная гипертензия у взрослых. РКО. 2020. URL: https: //scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf [Klinicheskie rekomendacii Arterial'naya gipertenziya u vzroslyh. RKO. 2020. URL: https: //scardio.ru/content/Guidelines/ Clinic_rek_AG_2020.pdf (in Russian).]
13. Трухан Д.И., Давыдов Е.Л., Дрокина О.В. Рациональная фармакотерапия артериальной гипертензии в реальной клинической практике сквозь призму лекарственной безопасности и мультиморбидности. Терапия. 2021; 2 (44): 141–52. DOI: 10.18565/therapy.2021.2.141-152 [Truhan D.I., Davydov E.L., Drokina O.V. Racional'naya farmakoterapiya arterial'noj gipertenzii v real'noj klinicheskoj praktike skvoz' prizmu lekarstvennoj bezopasnosti i mul'timorbidnosti. Terapiya. 2021; 2 (44): 141–52. DOI: 10.18565/therapy.2021.2.141-152 (in Russian).]
14. Burnier M, Bakris G, Williams B. Redefining diuretics use in hypertension: why select a thiazide-like diuretic? J Hypertens 2019; 37 (8): 1574–86. DOI: 10.1097/HJH.0000000000002088
15. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, metaanalyses, and meta-regression analyses of randomized trials. J Hypertens 2014; 32 (12): 2285–95. DOI: 10.1097/HJH.0000000 000000378
16. Chen P, Chaugai S, Zhao F, Wang DW. Cardioprotective Effect of Thiazide-Like Diuretics: A Meta-Analysis. Am J Hypertens 2015; 28 (12): 1453–63. DOI: 10.1093/ajh/hpv050
17. Roush GC, Abdelfattah R, Song S et al. Hydrochlorothiazide vs chlorthalidone, indapamide, and potassium-sparing/hydrochlorothiazide diuretics for reducing left ventricular hypertrophy: A systematic review and meta-analysis. J Clin Hypertens (Greenwich) 2018; 20 (10): 1507–15. DOI: 10.1111/jch.13386
18. Pareek AK, Messerli FH, Chandurkar NB et al. Efficacy of Low-Dose Chlorthalidone and Hydrochlorothiazide as Assessed by 24-h Ambulatory Blood Pressure Monitoring. J Am Coll Cardiol 2016; 67 (4): 379–89. DOI: 10.1016/j.jacc.2015.10.083
19. Messerli FH, Makani H, Benjo A et al. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol 2011; 57 (5): 590–600. DOI: 10.1016/j.jacc.2010.07.053
20. Boggia J, Li Y, Thijs L et al. Prognostic accuracy of day versus night ambulatory blood pressure: a cohort study. Lancet 2007; 370 (9594): 1219–29. DOI: 10.1016/S0140-6736 (07)61538-4
21. Fagard RH, Thijs L, Staessen JA et al. Night-day blood pressure ratio and dipping pattern as predictors of death and cardiovascular events in hypertension. J Hum Hypertens 2009; 23 (10): 645–53. DOI: 10.1038/jhh.2009.9
22. O'Brien E, Parati G, Stergiou G et al. European Society of Hypertension position paper on ambulatory blood pressure monitoring. J Hypertens 2013; 31 (9): 1731–68. DOI: 10.1097/HJH. 0b013e32 8363e964
23. Chrysant SG, Neller GK, Dillard B, Frohlich ED. Effects of diuretics on lipid metabolism in patients with essential hypertension. Angiology 1976; 27 (12): 707–11. DOI: 10.1177/000331977602701205.
24. Elliott WJ, Meyer PM. Incident diabetes in clinical trials of antihypertensive drugs: a network metaanalysis. Lancet 2007; 369 (9557): 201–7. DOI: 10.1016/S0140-6736 (07)60108-1.
25. Sica DA, Carter B, Cushman W, Hamm L. Thiazide and loop diuretics. J Clin Hypertens (Greenwich) 2011; 13 (9): 639–43. DOI: 10.1111/j.1751-7176.2011.00512.x
26. Lin J-J, Chang H-C, Ku C-T, Chen H-Y. Hydrochlorothiazide hypertension treatment induced metabolic effects in type 2 diabetes: a meta-analysis of parallel-design RCTs. Eur Rev Med Pharmacol Sci 2016; 20 (13): 2926–34. URL: https: //pubmed.ncbi.nlm.nih.gov/ 27424996/
27. Zhang X, Zhao Q. Association of thiazide-type diuretics with glycemic changes in hypertensive patients: a systematic review and metaanalysis of randomized controlled clinical trials. J Clin Hypertens (Greenwich) 2016; 18 (4): 342–51. DOI: 10.1111/jch.12679
28. Hripcsak G, Suchard MA, Shea S et al. Comparison of Cardiovascular and Safety Outcomes of Chlorthalidone vs Hydrochlorothiazide to Treat Hypertension. JAMA Intern Med 2020; 180 (4): 542–51. DOI: 10.1001/jamainternmed.2019.7454
29. Vongpatanasin W. Hydrochlorothiazide is not the most useful nor versatile thiazide diuretic. Curr Opin Cardiol 2015; 30 (4): 361–5. DOI: 10.1097/HCO.0000000000000178
30. Roush GC, Ernst ME, Kostis JB et al. Head-to-head comparisons of hydrochlorothiazide with indapamide and chlorthalidone: antihypertensive and metabolic effects. Hypertension 2015; 65 (5): 1041–6. DOI: 10.1161/HYPERTENSIONAHA.114.05021
31. Liang W, Ma H, Cao L et al. Comparison of thiazide-like diuretics versus thiazide-type diuretics: a meta-analysis. J Cell Mol Med 2017; 21 (11): 2634–42. DOI: 10.1111/jcmm.13205
32. Qin L, Zhang N, Ishigami J et al. Dyskalemia risk associated with fixed-dose anti-hypertensive medication combinations. J Hum Hypertens 2022; 36 (11): 989–95. DOI: 10.1038/s41371-021-00600-w
33. Lin Z, Li HL, Tsoi MF, Cheung BMY. Hypokalaemia associated with hydrochlorothiazide used in the treatment of hypertension in NHANES 1999-2018. J Hum Hypertens 2022. DOI: 10.1038/s41371- 022-00704-x
34. Lin Z, Cheung BMY, Tang V, Tsoi MF. Incidence of severe hypokalaemia in patients taking indapamide. Intern Emerg Med 2023; 18 (2): 549–57. DOI: 10.1007/s11739-023-03209-8
35. Ishani A, Cushman WC, Leatherman SM et al; Diuretic Comparison Project Writing Group. Chlorthalidone vs. Hydrochlorothiazide for Hypertension-Cardiovascular Events. N Engl J Med 2022; 387 (26): 2401–10. DOI: 10.1056/NEJMoa2212270
36. Гидрохлоротиазид: новые данные о безопасности. URL: http: //www.rlsnet.ru/news_1791.htm [Gidrohlorotiazid: novye dannye o bezopasnosti. URL: http: //www.rlsnet.ru/news_1791.htm (in Russian).]
37. Трухан Д.И., Лебедев О.И. Изменение органа зрения при заболеваниях внутренних органов. М.: Практическая медицина. 2014. URL: https: //elibrary.ru/item.asp?id=26002880 [Truhan D.I., Lebedev O.I. Izmenenie organa zreniya pri zabolevaniyah vnutrennih organov. M.: Prakticheskaya medicina. 2014. URL: https: //elibrary.ru/item.asp?id=26002880 (in Russian).]
38. Yang MC, Lin KY. Drug-induced Acute Angle-closure Glaucoma: A Review. Drug-induced Acute Angle-closure Glaucoma: A Review. J Curr Glaucoma Pract 2019; 13 (3): 104–9. DOI: 10.5005/jp-journals10078-1261
39. Geanon JD, Perkins TW. Bilateral acute angle-closure glaucoma associated with drug sensitivity to hydrochlorothiazide. Arch Ophthalmol 1995; 113 (10): 1231–2. DOI: 10.1001/archopht.1995. 01100100019012
40. Chen SH, Karanjia R, Chevrier RL, Marshall DH. Bilateral acute angle closure glaucoma associated with hydrochlorothiazide-induced hyponatraemia. BMJ Case Rep 2014; 2014: bcr2014206690. DOI: 10.1136/bcr-2014-206690
41. Roh Y-R, Woo SJ, Park KH. Acute-Onset Bilateral Myopia and Ciliochoroidal Effusion Induced by Hydrochlorothiazide. Korean Journal of Ophthalmology: KJO 2011; 25 (3): 214–7. DOI: 10.3341/kjo. 2011.25.3.214
42. Wu C, Pan H, Feng S et al. Low-dose topiramate and hydrochlorothiazide-associated early acute myopia and angle narrowing: A case report. Front Med (Lausanne) 2023; 10: 1062160. DOI: 10.3389/ fmed.2023.1062160
43. Mahesh G, Giridhar A, Saikumar SJ, Fegde S. Drug-induced acute myopia following chlorthalidone treatment. Indian J Ophthalmol 2007; 55 (5): 386–8. DOI: 10.4103/0301-4738.33830
44. Федеральная служба по надзору в сфере здравоохранения. Информационное письмо от 26.12.2018 № 01И-3093/18. О новых данных по безопасности лекарственных препаратов содержащих в качестве действующего вещества гидрохлоротиазид. URL: http: //roszdravnadzor.ru/drugs/monitpringlp/documents/ 56341 [Federal'naya sluzhba po nadzoru v sfere zdravoohraneniya. Informacionnoe pis'mo ot 26.12.2018 № 01I-3093/18. O novyh dannyh po bezopasnosti lekarstvennyh preparatov soderzhashchih v kachestve dejstvuyushchego veshchestva gidrohlorotiazid. URL: http: //roszdravnadzor.ru/drugs/monitpringlp/documents/56341 (in Russian).]
45. Pottegård A, Hallas J, Olesen M et.al. Hydrochlorothiazide use is strongly associated with risk of lip cancer. J Intern Med 2017; 282 (4): 322–31. DOI: 10.1111/joim.12629
46. Pedersen SA, Gaist D, Schmidt SAJ et al. Hydrochlorothiazide use and risk of nonmelanoma skin cancer: A nationwide case-control study from Denmark. J Am Acad Dermatol 2018; 78 (4): 673–81.e9. DOI: 10.1016/j.jaad.2017.11.042
47. Федеральная служба по надзору в сфере здравоохранения. Информационное письмо от 05.02.2019 №01И-318/19. О внесении изменений в инструкции по применению лекарственных препаратов, содержащих гидрохлоротиазид. URL: http: //roszdravnadzor.ru/drugs/monitpringlp/documents/57228 [Federal'naya sluzhba po nadzoru v sfere zdravoohraneniya. Informacionnoe pis'mo ot 05.02.2019 №01I-318/19. O vnesenii izmenenij v instrukcii po primeneniyu lekarstvennyh preparatov, soderzhashchih gidrohlorotiazid. URL: http: //roszdravnadzor.ru/ drugs/monitpringlp/documents/57228 (in Russian).]
48. Llamas-Molina JM, Navarro-Triviño FJ, Ruiz-Villaverde R. What Dermatologists Should Know About Thiazides. Actas Dermosifiliogr 2022; 113 (5): 498–504. DOI: 10.1016/j.ad.2021.12.015
49. Garrido PM, Borges-Costa J. Hydrochlorothiazide treatment and risk of non-melanoma skin cancer: Review of the literature. Rev Port Cardiol (Engl Ed) 2020; 39 (3): 163–70. DOI: 10.1016/ j.repc.2019.07.008
50. Lecaros-Astorga DA, Molina-Guarneros JA, Rodríguez-Jiménez P et al. Hydrochlorothiazide use and risk of non-melanoma skin cancer in Spain: A case/non-case study. Int J Clin Pharmacol Ther 2021; 59 (4): 280–8. DOI: 10.5414/CP203769
51. Becquart O, Guillot B, Bourrain J-L et al. Hydrochlorothiazide use and risk of skin cancers: A systematic review. Rev Med Interne 2019; 40 (9): 617–22. DOI: 10.1016/j.revmed.2019.04.008
52. Letellier T, Le Borgne F, Kerleau C et al; Divat Consortium. Association between Use of Hydrochlorothiazide and Risk of Keratinocyte Cancers in Kidney Transplant Recipients. Clin J Am Soc Nephrol 20207; 15 (12): 1804–13. DOI: 10.2215/CJN.02560220
53. Carney K, Cousins M. Does hydrochlorothiazide increase the incidence of skin, lip and oral cancer in a UK population? Evid Based Dent 2022; 23 (1): 38–9. DOI: 10.1038/s41432-022-0255-x
54. Eworuke E, Haug N, Bradley M et al. Risk of Nonmelanoma Skin Cancer in Association With Use of Hydrochlorothiazide-Containing Products in the United States. JNCI Cancer Spectr 2021; 5 (2): pkab009. DOI: 10.1093/jncics/pkab009
55. Rouette J, Yin H, Pottegård A et.al. Use of Hydrochlorothiazide and Risk of Melanoma and Nonmelanoma Skin Cancer. Drug Saf 2021; 44 (2): 245–54. DOI: 10.1007/s40264-020-01015-1
56. de Macedo Andrade AC, Felix FA, França GM et al. Hydrochlorothiazide use is associated with the risk of cutaneous and lip squamous cell carcinoma: A systematic review and meta-analysis. Eur J Clin Pharmacol 2022; 78 (6): 919–30. DOI: 10.1007/s00228-022-03299-x
57. Shao SC, Lai CC, Chen YH et al. Associations of thiazide use with skin cancers: a systematic review and meta-analysis. BMC Med 2022; 20 (1): 228. DOI: 10.1186/s12916-022-02419-9
58. Habel LA, Achacoso N, Fireman B et.al. Hydrochlorothiazide and risk of melanoma subtypes. Pharmacoepidemiol Drug Saf 2021; 30 (10): 1396–401. DOI: 10.1002/pds.5266
59. Adalsteinsson JA, Muzumdar S, Waldman R et al. Association between hydrochlorothiazide and the risk of in situ and invasive squamous cell skin carcinoma and basal cell carcinoma: A populationbased case-control study. J Am Acad Dermatol 2021; 84 (3): 669–75. DOI: 10.1016/j.jaad.2020.08.025
60. Damps T, Czuwara J, Warszawik-Hendzel O et al. The role of drugs and selected dietary factors in cutaneous squamous cell carcinogenesis. Postepy Dermatol Alergol 2021; 38 (2): 198–204. DOI: 10.5114/ada.2021.106196
61. Pottegård A, Bech BH, Pedersen SA, Christensen B. Use of hydrochlorothiazide in Denmark following publication of skin cancer risk findings. Pharmacoepidemiol Drug Saf 2021; 30 (11): 1611–6. DOI: 10.1002/pds.5350
62. Tchernev G, Oliveira N, Kandathil LJ. Baboon syndrome (SDRIFE) after valsartan/hydrochlorothiazide intake for several years. Dermatol Reports 2021; 14 (2): 9412. DOI: 10.4081/dr.2022.9412
63. Ferreira O, Mota A, Morais P et al. Symmetrical drug-related intertriginous and flexural exanthema (SDRIFE) induced by telmisartanhydrochlorothiazide. Cutan Ocul Toxicol 2010; 29 (4): 293–5. DOI: 10.3109/15569527.2010.491103
64. Федеральное государственное бюджетное учреждение «Научный центр экспертизы средств медицинского применения» (ФГБУ «НЦЭСМП» Минздрава России). Информационное письмо №4785 от 13 марта 2023 г. [Federal'noe gosudarstvennoe byudzhetnoe uchrezhdenie «Nauchnyj centr ekspertizy sredstv medicinskogo primeneniya» (FGBU «NCESMP» Minzdrava Rossii). Informacionnoe pis'mo №4785 ot 13 marta 2023 g. (in Russian).]
65. Levay ID. Hydrochlorothiazide-induced pulmonary edema. Drug Intell Clin Pharm 1984; 18 (3): 238–9. DOI: 10.1177/106002808401800311
66. González G, Ligueros M, Castro P et al. Adult respiratory distress syndrome associated with hydrochlorothiazide: a report of 2 cases and review of the literature. Rev Med Chil 1988; 116 (10): 1047–53. URL: https: //pubmed.ncbi.nlm.nih.gov/3077199/
67. Kavaru MS, Ahmad M, Hydrochlorothiazide-induced acute pulmonary edema. Amirthalingam KN. Cleve Clin J Med 1990; 57 (2): 181–4. DOI: 10.3949/ccjm.57.2.181
68. Nielsen-Kudsk JE, Knudsen AS, Sørensen PV. Pulmonary edema induced by hydrochlorothiazide/amiloride (Moduretic). Ugeskr Laeger 1991; 153 (11): 791–2. URL: https: //pubmed.ncbi.nlm.nih.gov/2008731/
69. Biron P, Dessureault J, Napke E. Acute allergic interstitial pneumonitis induced by hydrochlorothiazide. CMAJ 1991; 145 (1): 28–34. URL: https: //pubmed.ncbi.nlm.nih.gov/2049694/
70. Shieh CM, Chen CH, Tao CW et al. Hydrochlorothiazide-induced pulmonary edema: a case report and literature review. Zhonghua Yi Xue Za Zhi (Taipei) 1992; 50 (6): 495–9. URL: https: //pubmed.ncbi.nlm.nih.gov/1338027/#affiliation-1
71. Garcia MJ, Kidwai Z, Rosa J, Cooper EB. Thiazide-induced pulmonary edema: a case report. Conn Med 1992; 56 (4): 185–6. URL: https: //pubmed.ncbi.nlm.nih.gov/1606817/
72. Knowles SR, Wong GA, Rahim SA et al. Hydrochlorothiazide-induced noncardiogenic pulmonary edema: an underrecognized yet serious adverse drug reaction. Pharmacotherapy 2005; 25 (9): 1258–65. DOI: 10.1592/phco.2005.25.9.1258
73. Goetschalckx K, Ceuppens J, Van Mieghem W. Hydrochlorothiazideassociated noncardiogenic pulmonary oedema and shock: a case report and review of the literature. Acta Cardiol 2007; 62 (2): 215–20. DOI: 10.2143/AC.62.2.2020246
74. Jansson PS, Leisten DC, Sarkisian TM et al. Recurrent Hydrochlorothiazide-Induced Acute Respiratory Distress Syndrome Treated With Extracorporeal Membrane Oxygenation. J Emerg Med 2018; 55 (6): 836–40. DOI: 10.1016/j.jemermed.2018.09.019
75. Kane SP, Cohen E. Life-threatening idiopathic reaction to hydrochlorothiazide treated with veno-venous extracorporeal membrane oxygenation. Perfusion 2018; 33 (4): 320–2. DOI: 10.1177/0267659117745370
76. Traversa M, Collini A, Villois P et al. When a Diuretic Causes Pulmonary Oedema. Eur J Case Rep Intern Med 2018; 5 (6): 000864. DOI: 10.12890/2018_000864
77. Chauhan K, Pattharanitima P, Piani F et al. Prevalence and Outcomes Associated with Hyperuricemia in Hospitalized Patients with COVID-19. Am J Nephrol 2022; 53 (1): 78–86. DOI: 10.1159/ 000520355
78. Трухан Д.И. Новая коронавирусная инфекция (COVID-19) и заболевания / патологические состояния почек и мочевых путей. Клинический разбор в общей медицине. 2022; 1: 6–15. DOI: 10.47407/kr2022.3.1.00111 [Truhan D.I. Novaya koronavirusnaya infekciya (COVID-19) i zabolevaniya / patologicheskie sostoyaniya pochek i mochevyh putej. Clinical review for general practice. 2022; 1: 6–15. DOI: 10.47407/kr2022.3.1.00111 (in Russian).]
79. Трухан Д.И., Викторова И.А. Новая коронавирусная инфекция (COVID-19) и основные ревматические заболевания. Клинический разбор в общей медицине. 2023; 4 (1): 36–43. DOI: 10.47407/kr2023.4.1.00187 [Truhan D.I., Viktorova I.A. Novaya koronavirusnaya infekciya (COVID-19) i osnovnye revmaticheskie zabolevaniya. Clinical review for general practice. 2023; 4 (1): 36–43. DOI: 10.47407/ kr2023.4.1.00187 (in Russian).]
80. Choi HK, Soriano LC, Zhang Y, Rodríguez L.A. Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study. BMJ 2012; 344: d8190. DOI: 10.1136/bmj.d8190
81. Bruderer S, Bodmer M, Jick SS, Meier CR. Use of diuretics and risk of incident gout: a population-based case-control study. Arthritis Rheumatol 2014; 66 (1): 185–96. DOI: 10.1002/art.38203
82. Ueno S, Hamada T, Taniguchi S et al. Effect of Antihypertensive Drugs on Uric Acid Metabolism in Patients with Hypertension: Cross-Sectional Cohort Study. Drug Res (Stuttg) 2016; 66 (12): 628– 32. DOI: 10.1055/s-0042-113183
83. Переверзев А.П., Остроумова О.Д. Лекарственно-индуцированные гиперурикемия/подагра. Часть 2: отдельные лекарственные средства, прием которых ассоциирован с повышенным риском развития этих заболеваний. Терапия. 2021; 7: 159–69. DOI: 10.18565/therapy.2021.7.159-169 [Pereverzev A.P., Ostroumova O.D. Lekarstvenno-inducirovannye giperurikemiya/podagra. CHast' 2: otdel'nye lekarstvennye sredstva, priem kotoryh associirovan s povyshennym riskom razvitiya etih zabolevanij. Terapiya. 2021; 7: 159–69. DOI: 10.18565/therapy.2021.7.159-169 (in Russian).]
84. Waller PC, Ramsay LE. Predicting acute gout in diuretic-treated hypertensive patients. J Hum Hypertens 1989; 3 (6): 457–61. https: //pubmed.ncbi.nlm.nih.gov/2607519/
85. Hunter DJ, York M, Chaisson CE et al. Recent diuretic use and the risk of recurrent gout attacks: the online case-crossover gout study. J Rheumatol 2006; 33 (7): 1341–45. https: //pubmed.ncbi.nlm.nih. gov/16758506/
86. Savage PJ, Pressel SL, Curb JD, et al. Influence of long-term, lowdose, diuretic-based, antihypertensive therapy on glucose, lipid, uric acid, and potassium levels in older men and women with isolated systolic hypertension: the Systolic Hypertension in the Elderly Program. SHEP Cooperative Research Group. Arch Intern Med 1998; 158: 741– 51. DOI: 10.1001/archinte.158.7.741
87. Palmer B.F. Metabolic complications associated with use of diuretics. Semin Nephrol 2011; 31 (6): 542–52. DOI: 10.1016/j. semnephrol. 2011.09.009
88. Handler J. Managing hypertensive patients with gout who take thiazide. J Clin Hypertens (Greenwich) 2010; 12 (9): 731–35. DOI: 10.1111/j.1751-7176.2010.00346.x
89. Reyes AJ. Cardiovascular drugs and serum uric acid. Cardiovasc Drugs Ther 2003; 17 (5–6): 397–414. DOI: 10.1023/b: card.0000015855.02485.e3
90. Ben Salem C, Slim R, Fathallah N, Hmouda H. Drug-induced hyperuricaemia and gout. Rheumatology 2017; 56 (5): 679–88. DOI: 10.1093/rheumatology/kew293
91. Plante GE, Robillard C. Indapamide in the treatment of essential arterial hypertension: results of a controlled study. Curr Med Res Opin 1983; 8 (Suppl. 3): 59–66. DOI: 10.1185/03007998309109837
92. Weidmann P. Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised doubleblind studies. Drug Saf 2001; 24: 1155–65. DOI: 10.2165/00002018- 200124150-00006
93. Reilly RF, Peixoto AJ, Desir GV. The evidence-based use of thiazide diuretics in hypertension and nephrolithiasis. CJASN 2010; 5 (10): 1893–903. DOI: 10.2215/CJN.04670510
94. Musini VM, Nazer M, Bassett K, Wright JM. Blood pressure-lowering efficacy of monotherapy with thiazide diuretics for primary hypertension. Cochrane Database Syst Rev 2014; 5: CD003824. DOI: 10.1002/14651858.CD003824.pub2
95. Трухан Д.И., Давыдов Е.Л. Место и роль терапевта и врача общей практики в курации коморбидных пациентов в период пандемии новой коронавирусной инфекции (COVID-19): акцент на реабилитационный этап. Фарматека. 2021; 13: 44–53. DOI: 10.18565/pharmateca.2021.13.44-53 [Truhan D.I., Davydov E.L. Mesto i rol' terapevta i vracha obshchej praktiki v kuracii komorbidnyh pacientov v period pandemii novoj koronavirusnoj infekcii (COVID-19): akcent na reabilitacionnyj etap. Farmateka. 2021; 13: 44–53. DOI: 10.18565/pharmateca. 2021.13.44-53 (in Russian).]
96. Трухан Д.И. Коморбидный пациент на терапевтическом приеме в период пандемии COVID-19. Актуальные аспекты реабилитационного периода. Фарматека. 2022; 29 (13): 15–24. DOI: 10.18565/pharmateca.2022.13.15-24 [Truhan D.I. Komorbidnyj pacient na terapevticheskom prieme v period pandemii COVID-19. Aktual'nye aspekty reabilitacionnogo perioda. Farmateka. 2022; 29 (13): 15–24. DOI: 10.18565/pharmateca.2022.13.15-24 (in Russian).]
97. Мазуров А.Л., Трухан Д.И. Сравнительная характеристика индапамида и гидрохлоротиазида. Современные наукоемкие технологии. 2010; 2: 100–1. URL: https: //elibrary.ru/item. asp?id=13042875 [Mazurov A.L., Truhan D.I. Sravnitel'naya harakteristika indapamida i gidrohlorotiazida. Sovremennye naukoemkie tekhnologii. 2010; 2: 100–1. URL: https: //elibrary.ru/item.asp?id=13042875 (in Russian).]
98. Павлова Т.В. Роль диуретиков в лечении АГ. Справочник поликлинического врача. 2013; 7–8: 37–41. URL: https: //elibrary.ru/ item.asp?id=22149450 [Pavlova T.V. Rol' diuretikov v lechenii AG. Spravochnik poliklinicheskogo vracha. 2013; 7–8: 37–41. URL: https: //elibrary.ru/item. asp?id=22149450 (in Russian).]
99. Недогода С.В. Диуретики при артериальной гипертензии: ангелы и демоны. Российский кардиологический журнал. 2013; 3: 62– 6. URL: https: //elibrary.ru/item.asp?id=19121461 [Nedogoda S.V. Diuretiki pri arterial'noj gipertenzii: angely i demony. Rossijskij kardiologicheskij zhurnal. 2013; 3: 62–6. URL: https: //elibrary.ru/item.asp?id=19121461 (in Russian).]
100. Трухан Д.И., Филимонов С.Н. Лечение артериальной гипертензии I–II стадий у пациентов с риском сердечно-сосудистых осложнений выше умеренного в реальной клинической практике: возможности индапамида в составе комбинированной терапии. Терапия. 2021; 5 (47): 173–83. DOI: 10.18565/therapy.2021.5.173-183 [Truhan D.I., Filimonov S.N. Lechenie arterial'noj gipertenzii I–II stadij u pacientov s riskom serdechno-sosudistyh oslozhnenij vyshe umerennogo v real'noj klinicheskoj praktike: vozmozhnosti indapamida v sostave kombinirovannoj terapii. Terapiya. 2021; 5 (47): 173–83. DOI: 10.18565/therapy.2021.5.173-183 (in Russian).]
101. Zhang Y, Agnoletti D, Safar ME, Blacher J. Effect of antihypertensive agents on blood pressure variability: the Natrilix SR versus candesartan and amlodipine in the reduction of systolic blood pressure in hypertensive patients (X-CELLENT) study. Hypertension 2011; 58 (2): 155–60. DOI: 10.1161/HYPERTENSIONAHA.111.174383
102. Waeber B, Rotaru C, Feihl F. Position of indapamide, a diuretic with vasorelaxant activities, in antihypertensive therapy. Expert Opin Pharmacother 2012; 13 (10): 1515–26. DOI: 10.1517/14656566. 2012.698611
103. Brodszky V, Nagy V, Farsang C et–al. The efficacy of indapamide in different cardiovascular outcome-meta-analysis. Orv Hetil 2007; 148 (26): 1203–11. DOI: 10.1556/OH.2007.28046
104. Nádházi Z, Dézsi CA. The Results of ACES (Antihypertensive Combinations' Long Term Efficacy Comparing Study): Analysis of Metabolic Effects of Antihypertensive Combination Therapies. Clin Drug Investig 2016; 36 (10): 819–27. DOI: 10.1007/s40261-016-0431-x
105. Janega P, Kojsová S, Jendeková L et al. Indapamide-induced prevention of myocardial fibrosis in spontaneous hypertension rats is not nitric oxide-related. Physiol Res 2007; 56 (6): 825–8. URL: https: //pubmed.ncbi.nlm.nih.gov/18197750
106. Jungmann E. Prevention and treatment of diabetic nephropathy in older patients. Drugs Aging 2003; 20 (6): 419–35. DOI: 10.2165/00002512-200320060-00002
107. Waeber B. Managing hypertension in high-risk patients: lessons and promises from the STRATHE and ADVANCE trials. J Hypertens Suppl 2006; 24 (3): S19–27. DOI: 10.1097/01.hjh.0000229465. 09610.b6
108. Heerspink HJ, Ninomiya T, Perkovic V et al; ADVANCE Collaborative Group. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010; 31 (23): 2888–96. DOI: 10.1093/eurheartj/ ehq139
109. Aubert I, Djian F, Rouffy J. Beneficial effects of indapamide on lipoproteins and apoproteins in ambulatory hypertensive patients. Am J Cardiol 1990; 65 (17): 77H-80H. DOI: 10.1016/0002-9149 (90)90349-6
110. Мамедов М.Н. Возможности применения индапамида на различных этапах сердечно-сосудистого континуума и в отдельных группах пациентов. Российский кардиологический журнал. 2010; 6: 107–11. URL: https: //elibrary.ru/item. asp?id=15518059 [Mamedov M.N. Vozmozhnosti primeneniya indapamida na razlichnyh etapah serdechno-sosudistogo kontinuuma i v otdel'nyh gruppah pacientov. Rossijskij kardiologicheskij zhurnal. 2010; 6: 107–11. URL: https: //elibrary.ru/item.asp?id=15518059 (in Russian).]
111. Akbari P, Khorasani-Zadeh A. Treasure Island (FL): StatPearls Publishing; 2023 Jan. URL: https: //pubmed.ncbi.nlm.nih.gov/ 30422513/
112. Марцевич С.Ю., Кутишенко Н.П., Деев А.Д., Якусевич В.В. Изучение эффективности и переносимости препарата индап в сравнении с препаратами арифон и арифон ретард у больных мягкой и умеренной артериальной гипертонией, назначаемых как в виде монотерапии, так и в комбинации с ингибиторами АПФ. Многоцентровое, открытое, рандомизированное перекрестное исследование. Российский кардиологический журнал. 2006; 2: 73–7. URL: https: //elibrary.ru/item.asp?id=10133950 [Marcevich S.Yu., Kutishenko N.P., Deev A.D., YAkusevich V.V. Izuchenie effektivnosti i perenosimosti preparata indap v sravnenii s preparatami arifon i arifon retard u bol'nyh myagkoj i umerennoj arterial'noj gipertoniej, naznachaemyh kak v vide monoterapii, tak i v kombinacii s ingibitorami APF. Mnogocentrovoe, otkrytoe, randomizirovannoe perekrestnoe issledovanie. Rossijskij kardiologicheskij zhurnal. 2006; 2: 73–7. URL: https: //elibrary.ru/item. asp?id=10133950 (in Russian).]
113. Трухан Д.И., Павлова Т.В., Викторова И.А. Оптимизация немедикаментозного и медикаментозного воздействия на патогенетические факторы развития и течения артериальной гипертензии в рамках новой научно-исследовательской образовательной оздоровительной программы ПЕРСПЕКТИВА. Справочник поликлинического врача. 2012. 11: 18–22. URL: https: //elibrary.ru/item.asp?id=23502186 [Truhan D.I., Pavlova T.V., Viktorova I.A. Optimizaciya nemedikamentoznogo i medikamentoznogo vozdejstviya na patogeneticheskie faktory razvitiya i techeniya arterial'noj gipertenzii v ramkah novoj nauchno-issledovatel'skoj obrazovatel'noj ozdorovitel'noj programmy PERSPEKTIVA. Spravochnik poliklinicheskogo vracha. 2012. 11: 18–22. URL: https: //elibrary.ru/item.asp?id=23502186 (in Russian).]
114. Сыров А.В., Минушкина Л.О. Выбор оптимального тиазидоподобного диуретика у пациентов с артериальной гипертензией. Терапия. 2021; 1 (43): 172–180. DOI: 10.18565/therapy.2021.1.172- 180 [Syrov A.V., Minushkina L.O. Vybor optimal'nogo tiazidopodobnogo diuretika u pacientov s arterial'noj gipertenziej. Terapiya. 2021; 1 (43): 172–180. DOI: 10.18565/therapy.2021.1.172-180 (in Russian).]
115. Сыров А.В. Применение индапамида в клинической практике. Терапия. 2021; 10 (52): 188–94. DOI: 10.18565/therapy.2021. 10.188-194 [Syrov A.V. Primenenie indapamida v klinicheskoj praktike. Terapiya. 2021; 10 (52): 188–94. DOI: 10.18565/therapy.2021.10.188- 194 (in Russian).]
116. Остроумова О.Д., Полякова О.А., Листратов А.И. и др. Тиазидные и тиазидоподобные диуретики: как правильно сделать выбор? Кардиология. 2022; 1: 89–97. DOI: 10.18087/cardio. 2022.1.n1862 [Ostroumova O.D., Polyakova O.A., Listratov A.I. et al. Tiazidnye i tiazidopodobnye diuretiki: kak pravil'no sdelat' vybor? Kardiologiya. 2022; 1: 89–97. DOI: 10.18087/cardio.2022.1.n1862 (in Russian).]
117. Полякова О.А., Остроумова О.Д., Араблинский А.В. Лекарственная безопасность и полиморбидность как важные составляющие рациональной фармакотерапии в кардиологии. Терапия. 2022; 4 (56): 141–8. DOI: 10.18565/therapy.2022.4.141-148 [Polyakova O.A., Ostroumova O.D., Arablinskij A.V. Lekarstvennaya bezopasnost' i polimorbidnost' kak vazhnye sostavlyayushchie racional'noj farmakoterapii v kardiologii. Terapiya. 2022; 4 (56): 141–8. DOI: 10.18565/therapy.2022.4.141-148 (in Russian).]
For citation:Trukhan D.I., Bagisheva N.V. Rational pharmacotherapy of arterial hypertension in real clinical practice: diuretics through drug safety. Clinical review for general practice. 2023; 4 (4): 48–59. DOI: 10.47407/kr2023.4.4.00256
All accepted articles publish licensed under a Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) which allows users to read, copy, distribute and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited properly.